The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

She related the onset to significant stress at her job. Unknown. Biopsy showed lichen simplex chronicus. There are no clinical manifestations. Some areas of the skin may be predisposed to pruritus ...

Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES REAL ESTATE CLASSIFIEDS EVENTS PETS CONTACT US ADVERTISING ...

2,4 Psoriasis, lichen planus, contact dermatitis, mycosis fungoides, and tinea corporis are disorders that mimic LSC. These conditions often can be differentiated from LSC by distribution and ...

Your board-certified dermatologist is trained to diagnose and treat conditions like lichen planus, which can affect your skin, hair, and nails Your dermatologist’s training includes recognizing the ...

Oral lichen planus (OLP), a T-lymphocyte-mediated disease of the oral mucosa, has a complex pathogenesis that involves a number of factors. The disease is characterized by recurrent episodes and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...